Kosuke Ebina, Yoshio Nagayama, Masafumi Kashii, Hideki Tsuboi, Gensuke Okamura, Akira Miyama, Yuki Etani, Takaaki Noguchi, Makoto Hirao, Taihei Miura, Yuji Fukuda, Takuya Kurihara, Ken Nakata, Seiji Okada
UNLABELLED: The impact of ROMO on the width of anabolic windows and the increase in BMD was reduced in the RA group compared to the non-RA group, and this reduction was associated with correlations to RA-related factors. PURPOSE: To investigate the effects of romosozumab (ROMO) in postmenopausal osteoporosis, with and without comorbid rheumatoid arthritis (RA). METHODS: In this retrospective, case-controlled, multicenter study, 171 postmenopausal patients who did not receive oral glucocorticoid, comprising 59 in the RA group and 121 in the non-RA group, received uninterrupted ROMO treatment for 12 months...
January 31, 2024: Osteoporosis International